6 research outputs found
Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)
Background: Mesenchymal stromal cells (MSCs) are a promising option to treat knee osteoarthritis (OA). Their safety
and usefulness have been reported in several short-term clinical trials but less information is available on the longterm efects of MSC in patients with osteoarthritis. We have evaluated patients included in our previous randomized
clinical trial (CMM-ART, NCT02123368) to determine their long-term clinical efect.
Materials: A phase I/II multicenter randomized clinical trial with active control was conducted between 2012 and
2014. Thirty patients diagnosed with knee OA were randomly assigned to Control group, intraarticularly administered
hyaluronic acid alone, or to two treatment groups, hyaluronic acid together with 10×106
or 100×106
cultured autol‑
ogous bone marrow-derived MSCs (BM-MSCs), and followed up for 12 months. After a follow up of 4 years adverse
efects and clinical evolution, assessed using VAS and WOMAC scorings are reported.
Results: No adverse efects were reported after BM-MSCs administration or during the follow-up. BM-MSCs-adminis‑
tered patients improved according to VAS, median value (IQR) for Control, Low-dose and High-dose groups changed
from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 7 (6, 7), 2 (2, 5) and 3 (3, 4), respectively at the end of follow up (Low-dose vs Control
group, p=0.01; High-dose vs Control group, p=0.004). Patients receiving BM-MSCs also improved clinically accord‑
ing to WOMAC. Control group showed an increase median value of 4 points (−11;10) while Low-dose and Highdose groups exhibited values of −18 (−28;−9) and −10 (−21;−3) points, respectively (Low-dose vs Control group
p=0.043). No clinical diferences between the BM-MSCs receiving groups were found.
Conclusions: Single intraarticular injection of in vitro expanded autologous BM-MSCs is a safe and feasible proce‑
dure that results in long-term clinical and functional improvement of knee OA
Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.
Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.
Methods: A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10x10(6), 50x10(6) and 100x10(6) cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.
Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.
Conclusions:.
IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage
Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs)
have shown benefit in other inflammatory diseases.
Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow
autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.
Methods: A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial
administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first
escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106 and
100×106 cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with
pulmonary function testing, 6-min walk test and St George’s Respiratory Questionnaire was done at 1, 2, 3, 6
and 12 months, and with computed tomography at 3, 6 and 12 months.
Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from
treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before
treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events
were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial
decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at
3 months and three (23%) at 12 months.
Conclusions: The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in
IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic
instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous
MSCs in IPF patients
IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage
Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs)
have shown benefit in other inflammatory diseases.
Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow
autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.
Methods: A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial
administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first
escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106 and
100×106 cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with
pulmonary function testing, 6-min walk test and St George’s Respiratory Questionnaire was done at 1, 2, 3, 6
and 12 months, and with computed tomography at 3, 6 and 12 months.
Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from
treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before
treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events
were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial
decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at
3 months and three (23%) at 12 months.
Conclusions: The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in
IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic
instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous
MSCs in IPF patients
Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.
Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.
Methods: A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10x10(6), 50x10(6) and 100x10(6) cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.
Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.
Conclusions:.
Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)
Background: Mesenchymal stromal cells (MSCs) are a promising option to treat knee osteoarthritis (OA). Their safety
and usefulness have been reported in several short-term clinical trials but less information is available on the longterm efects of MSC in patients with osteoarthritis. We have evaluated patients included in our previous randomized
clinical trial (CMM-ART, NCT02123368) to determine their long-term clinical efect.
Materials: A phase I/II multicenter randomized clinical trial with active control was conducted between 2012 and
2014. Thirty patients diagnosed with knee OA were randomly assigned to Control group, intraarticularly administered
hyaluronic acid alone, or to two treatment groups, hyaluronic acid together with 10×106
or 100×106
cultured autol‑
ogous bone marrow-derived MSCs (BM-MSCs), and followed up for 12 months. After a follow up of 4 years adverse
efects and clinical evolution, assessed using VAS and WOMAC scorings are reported.
Results: No adverse efects were reported after BM-MSCs administration or during the follow-up. BM-MSCs-adminis‑
tered patients improved according to VAS, median value (IQR) for Control, Low-dose and High-dose groups changed
from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 7 (6, 7), 2 (2, 5) and 3 (3, 4), respectively at the end of follow up (Low-dose vs Control
group, p=0.01; High-dose vs Control group, p=0.004). Patients receiving BM-MSCs also improved clinically accord‑
ing to WOMAC. Control group showed an increase median value of 4 points (−11;10) while Low-dose and Highdose groups exhibited values of −18 (−28;−9) and −10 (−21;−3) points, respectively (Low-dose vs Control group
p=0.043). No clinical diferences between the BM-MSCs receiving groups were found.
Conclusions: Single intraarticular injection of in vitro expanded autologous BM-MSCs is a safe and feasible proce‑
dure that results in long-term clinical and functional improvement of knee OA